Targeting TLR9 agonists to secondary lymphoid organs induces potent immune responses against HBV infection

Despite the existence of a prophylactic vaccine against hepatitis B virus (HBV), chronic hepatitis B virus (CHB) infection remains the leading cause of cirrhosis and liver cancer in developing countries. Because HBV persistence is associated with insufficient host immune responses to the infection,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ushach, Irina, Zhu, Ren, Rosler, Elen, Pandey, Rajendra K., De Costa, N. Tilani S., Pourshahian, Soheil, Han, Qinglin, Li, Chris, Beigelman, Leonid, Gryaznov, Sergei M., Yun, Theodore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857595/
https://www.ncbi.nlm.nih.gov/pubmed/35228903
http://dx.doi.org/10.1016/j.omtn.2022.01.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857595/
https://www.ncbi.nlm.nih.gov/pubmed/35228903
http://dx.doi.org/10.1016/j.omtn.2022.01.020

Ejemplares similares